Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update

Abeona Therapeutics Inc (NASDAQ:ABEOGet Free Report) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 1,560,000 shares, an increase of 100.4% from the January 31st total of 778,500 shares. Based on an average daily trading volume, of 287,500 shares, the days-to-cover ratio is presently 5.4 days. Currently, 6.7% of the company’s shares are short sold.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $7.81 on Friday. The company’s fifty day simple moving average is $5.55 and its 200-day simple moving average is $4.66. Abeona Therapeutics has a 52 week low of $2.24 and a 52 week high of $7.87.

Insider Transactions at Abeona Therapeutics

In other news, Director Mark Alvino sold 7,084 shares of Abeona Therapeutics stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $5.11, for a total transaction of $36,199.24. Following the completion of the sale, the director now directly owns 62,816 shares in the company, valued at $320,989.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Citigroup Inc. acquired a new position in shares of Abeona Therapeutics during the first quarter worth $27,000. Tower Research Capital LLC TRC bought a new stake in shares of Abeona Therapeutics in the third quarter worth $43,000. GSA Capital Partners LLP bought a new stake in shares of Abeona Therapeutics in the third quarter worth $49,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Abeona Therapeutics in the first quarter worth $51,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Abeona Therapeutics in the second quarter worth $52,000. 43.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 19th.

Get Our Latest Stock Report on ABEO

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.